Claims for Patent: 12,303,506

Summary for Patent: 12,303,506

Title:	Trabectedin composition
Abstract:	The present disclosure provides a stable, ready-to-dilute injectable pharmaceutical composition comprising trabectedin and at least one pharmaceutically acceptable excipient, wherein the composition is free of ethanol.
Inventor(s):	Krishna Mohan Chilakala, Nagamalleswara Rao BEERAKA, Ramesh MANTRI, Hanumantha Rao Kamma, Janos Vaczi
Assignee:	Extrovis AG
Application Number:	US17/931,831
Patent Claims:	1. A stable ready-to-dilute injectable pharmaceutical composition comprising (i) a therapeutically effective amount of trabectedin of about 0.05 mg/ml and (ii) a pharmaceutically acceptable carrier consisting of one pharmaceutically acceptable solvent, one pharmaceutically acceptable pH-adjusting agent, and one pharmaceutically acceptable stabilizing agent, wherein the composition is free of ethanol, has a pH of about 2.5 to about 5, and wherein when stored for 3 months at about 2 degrees Celsius to about 8 degrees Celsius, or for 3 months at about 25 degrees Celsius, the composition has (a) not more than 3.0% of total impurities, (b) not more than 0.5% of desacetyl trabectedin impurity and (c) not more than 0.5% of dehydroxy trabectedin impurity. 2. The stable ready-to-dilute injectable pharmaceutical composition of claim 1, wherein the solvent is selected from the group consisting of propylene glycol, polyethylene glycol, dimethyl acetamide, solketal, glycerol formal, acetone, glycerol, glycofurol, diethylene glycol monoethyl ether, dimethyl sulfoxide, N-methyl-2-pyrrolidone, water for injection, dimethyl formamide, aqueous solutions of disaccharides and mixtures thereof. 3. The stable ready-to-dilute injectable pharmaceutical composition of claim 2 wherein the solvent is propylene glycol. 4. The stable ready-to-dilute injectable pharmaceutical composition of claim 2, wherein the solvent is present in an amount of about 0.001 ml to about 1 ml per ml of the composition. 5. The stable ready-to-dilute injectable pharmaceutical composition of claim 1, wherein the pH-adjusting agent is selected from the group consisting of acetic acid, glacial acetic acid, tartaric acid, lactic acid, hydrochloric acid, benzene sulfonic acid, boric acid, citric acid, triethanolamine, orthophosphoric acid, succinic acid, fumaric acid, monoethanolamine, sodium carbonate, sodium bicarbonate, diethanolamine, magnesium aluminium silicates, maleic acid, malic acid, sodium hydroxide, magnesium oxide, calcium carbonate, monobasic sodium phosphate, gluconic acid, tartaric acid, dibasic sodium phosphate, magnesium carbonate, sulfuric acid and mixtures thereof. 6. The stable ready-to-dilute injectable pharmaceutical composition of claim 5, wherein the pH-adjusting agent is lactic acid. 7. The stable ready-to-dilute injectable pharmaceutical composition of claim 1, wherein the stabilizing agent is selected from the group consisting of glycine, 1-arginine, phenylalanine, histidine, acetylcysteine, citrulline, lysine, and isoleucine, methionine, cysteine and their pharmaceutically acceptable salts, and mixtures thereof. 8. The stable ready-to-dilute injectable pharmaceutical composition of claim 1 wherein at least about 90% purity of the trabectedin is retained after storage at about 2 degrees Celsius to about 8 degrees Celsius. 9. A stable ready-to-dilute injectable pharmaceutical composition comprising (i) a therapeutically effective amount of trabectedin, (ii) propylene glycol, (iii) lactic acid in an amount sufficient to provide a pH of about 2.5 to 5.0 (iv) glycine and (v) sterile water for injection, and wherein when stored for 3 months at about 2 degrees Celsius to about 8 degrees Celsius, or for 3 months at about 25 degrees Celsius, the composition has (a) not more than 3.0% of total impurities, (b) not more than 0.5% of desacetyl trabectedin impurity and (c) not more than 0.5% of dehydroxy trabectedin impurity. 10. The stable ready-to-dilute injectable pharmaceutical composition of claim 9 wherein at least about 90% purity of the trabectedin is retained after storage at about 2 degrees Celsius to about 8 degrees Celsius.